chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Have had pain in left arm (muscle soreness) since receiving flu shot on 11/28/00. Pain is present on upward movement of arm and worse with lifting or pushing.
Wheezing, sneezing, fever, coughing, runny nose, diarrhea, headaches, sore throat, aching body
24 hours later at about 2 PM red mark around injection site. It was large as big as silver dollar. Did not itch, felt tired and had a headache. By next morning spot was larger, tender, hot. Went by clinic and PA said it was a little skin infection that would go away. 10/5 Went by clinic again and they said that it was a skin infection that required prescription so was given cephalexin but it did not help. 10/6/13 Went to ER. Red area was getting larger, doctor gave new medication clindamycin. Today it doesn't look as red but tender. Red area migrating towards elbow. 2 different red spots, looks like bad sunburn.
swollen red area at injection site continued for 2 days given Benadryl and cool compresses returned to MD on 12/2/2010 and told she has a chicken pox at site given once daily antihistimine for 1 week
7/27/2021 @ 9:00pm broke out in hives, swollen lips & eyes, tight chest, short of breath. Took Benadryl for treatment. 7/28/2021 @ 10:30am broke out in hives. Took Benadryl for treatment. 7/29/2021 @ 03:00am broke out in hives. Took Benadryl. 7/29/2021 @ 12:30pm woke up with palpitations and shaking. No treatment. Called employee health to let them know to document my reactions. I was told by employee health @12:38pm to follow up with my PCP if this continues or worsens.
12x12 cm area of redness and warmth. admitted to hospital with dx acute cellulitis
5 days p/vax devel rash on face, chest & back;today has rash on palms of hands & bottom of feet;child has sore throat but no fever 14SEp98;parents states MD felt rash from MMR vax;
BLOOD CLOT IN RIGHT LUNG; This spontaneous report received from a patient through a company representative concerned a patient of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number: unknown and expiry: unknown) dose, 1 total, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced blood clot in right lung. Patient was on eliquis (apixaban). As per reporter, "I took the J&J vaccine and ended up with a blood clot in my right lung. Now on Eloquis". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of blood clot in right lung was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20220207350-JANSSEN COVID-19 VACCINE Ad26.COV2.S- BLOOD CLOT IN RIGHT LUNG. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Information has been received from a registered nurse concerning a 67 year old female patient with no medical history reported, who on 21-JUL-2008 was vaccinated intramuscularly into the arm with a dose of PNEUMOVAX 23 (Lot 658673/099U or 659150/1384U). On 21-JUL-2008 the patient reported severe arm pain at the injection site, minor swelling, and unbearable pain, with no warmth and no redness. The patient was seen in the office on 22-JUL-2008. No diagnostic laboratory studies were performed. Subsequently, the patient recovered. No product quality complaint was involved. The nurse requested lot checks for both of the reported lots. The reporter considered severe arm pain, minor swelling and unbearable pain to be disabling. Additional information has been requested.
No adverse effects; inadvertently administered a dose of MMR  via the intramuscular route rather than the recommed subcutaneous; This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No information regarding the patients' pertinent medical history, drug reactions, allergies and concomitant therapies was provided.  On 13-APR-2019, the patient was inadvertently vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection (dose not reported) lot # R024906, expiration date 30-AUG-2020, via the intramuscular route rather than the recommended subcutaneous route, for prophylaxis. No adverse effects were reported.  Albumin status for measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) has been verified as recombinant human albumin (rHA).
COVID-19; Cold symptoms; Cough; Loss of smell; Temp 100.6; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jul-2021, the patient experienced COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6). At the time of the report, COVID-19 (COVID-19), NASOPHARYNGITIS (Cold symptoms), COUGH (Cough), ANOSMIA (Loss of smell) and PYREXIA (Temp 100.6) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jul-2021, Body temperature: 100.6 (High) Temp 100.6. On 15-Jul-2021, SARS-CoV-2 test: positive (Positive) Tested positive for COVID.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Teatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: Non Significant follow up - Patient initial updated.
Beginning approx. 5 hours after receiving vaccine, patient began acting extremely agitated, restless, and cried contiually and inconsolobly for two and a half hours before beginning to calm. Patient eventually stopped crying but was irritable and uncomfortable for the rest of the evening. No appetite at dinner and restless through the night. Similar events occured with first vaccinations on 11/12/2008.
Child had vomiting, dizziness, that proceeded to headaches, over ensuing weeks, child developed amnesia, dystonia, and lost ability to walk; child had multiple pseudoseizures.
Tingling  in  both  hands; Pain in both hands; inflammation and burning in my hands; inflammation and burning in my hands; This spontaneous case was reported by a consumer and describes the occurrence of INFLAMMATION (inflammation and burning in my hands), BURNING SENSATION (inflammation and burning in my hands), PARAESTHESIA (Tingling  in  both  hands) and PAIN IN EXTREMITY (Pain in both hands) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     Concomitant products included ESTRADIOL BENZOATE (ESTRADIOL [ESTRADIOL BENZOATE]) for Menopause, CORTISONE for an unknown indication, GABAPENTIN (NEURONTIN), IBUPROFEN (ADVIL [IBUPROFEN]), MELOXICAM (MOBIC) and LIDOCAINE.    On 21-Jan-2021 at 11:21 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jan-2021, the patient experienced INFLAMMATION (inflammation and burning in my hands) and BURNING SENSATION (inflammation and burning in my hands). On 03-Feb-2021, the patient experienced PARAESTHESIA (Tingling  in  both  hands). 03-Feb-2021, the patient experienced PAIN IN EXTREMITY (Pain in both hands). At the time of the report, INFLAMMATION (inflammation and burning in my hands), BURNING SENSATION (inflammation and burning in my hands), PARAESTHESIA (Tingling  in  both  hands) and PAIN IN EXTREMITY (Pain in both hands) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered INFLAMMATION (inflammation and burning in my hands), BURNING SENSATION (inflammation and burning in my hands), PARAESTHESIA (Tingling  in  both  hands) and PAIN IN EXTREMITY (Pain in both hands) to be possibly related.    Patient subsequently been to 7 different doctors for a diagnosis followed by 2 MRIs and several injections of cortisone  Patient went to an intervention Neurologist for special nerve blocks on July 21st and  still experiencing pain and the loss of feeling to fingers, causing the inability to do normal daily activities.  Patient had an autoimmune inflammatory response to the vaccines. patient stated that - Feb 11: Hand  surgeon,  Dr.;  Feb 16: Dr., neurologist;  Feb 18: back  to  Dr. forcortisone  shot.   This case was linked to MOD-2021-294574 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 25-Aug-2021: Significant Follow up includes: added patient race and ethnicity information and estradiol patch as a concomitant drug and pain in both hands and tingling in hands.
Received vaccine on Thursday evening at 6:00pm.  On Saturday, I felt that something has changed with my hearing.  On Sunday morning I was deaf in my left ear.
This case was reported by a healthcare professional and described the occurrence of swelling injection site in a 34-year-old male subject who was vaccinated with TWINRIX (GlaxoSmithKline). On 27 January 2011 the subject received 2nd dose of TWINRIX (1 ml, unknown, left arm). On 27 January 2011, immediately after vaccination with TWINRIX, the subject experienced swelling injection site and injection site redness. On 27 January 2011, immediately after vaccination with TWINRIX, the subject experienced swelling, injection site redness; the size was described as a fourth to half a dollar size. Intervention to prevent further swelling was performed at the physician's office and included application of ice. The healthcare professional considered the events were clinically significant (or requiring intervention). The subject was treated with Ice pack. One day later on 28 January 2011, the swelling injection site and injection site redness were resolved. This is the second of two cases by the healthcare professional; for the first case see A0910755A. Follow-up information was received on 16 February 2011. It was reported that TWINRIX was administered intramuscularly. The events began immediately after vaccination on 27 January 2011 and resolved the following day on 28 January 2011. In the reporter's opinion, the events were considered probably related to treatment with TWINRIX.
44 days after receiving the first dose; Soreness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (44 days after receiving the first dose) and VACCINATION SITE PAIN (Soreness at the injection site) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) and High blood pressure medications for an unknown indication.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced VACCINATION SITE PAIN (Soreness at the injection site). On 14-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (44 days after receiving the first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (44 days after receiving the first dose) and VACCINATION SITE PAIN (Soreness at the injection site) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment information was reported. Action taken with mRNA-1273 in response to the events was not Applicable
6;AM heart racing Temperature 104.1 took Tylanol PM . Chills all day current temperature 102. Temperature changed thruogh out the day. Sometimes 100 sometimes 98.7. I had Covid a year ago in mid- march. 10 days to two weeks with fever. lost 8 pounds. Was not hospitalized.
3 weeks after receiving the Pfizer Bivalent vaccine, I woke up with Vertigo (dizziness).
patient was inadvertently given a third dose / on 26Jan2021; This case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 78-year-old female patient who received Herpes zoster (Shingrix) (batch number BA56K, expiry date unknown) for prophylaxis.   Concurrent medical conditions included chronic obstructive pulmonary disease.   On 26th January 2021, the patient received the 3rd dose of Shingrix. On 26th January 2021, unknown after receiving Shingrix, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.  Additional details were provided as follows: The pharmacist reported that the patient was inadvertently administered third dose of Shingrix, which led to extra dose administered. The pharmacist closed out the patient record before specialist could obtain the date on the call. The reporter consented to follow up.
itching; hot to touch; injection site red circles; local redness; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (local redness), PRURITUS (itching), FEELING HOT (hot to touch) and INJECTION SITE ERYTHEMA (injection site red circles) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     Concurrent medical conditions included Sensitive skin, Skin disorder NOS and Allergy to antibiotic.    On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Jan-2021, the patient experienced ERYTHEMA (local redness). On 06-Feb-2021, the patient experienced INJECTION SITE ERYTHEMA (injection site red circles). On 12-Feb-2021, the patient experienced PRURITUS (itching) and FEELING HOT (hot to touch). On 10-Feb-2021, INJECTION SITE ERYTHEMA (injection site red circles) had resolved. At the time of the report, ERYTHEMA (local redness) outcome was unknown and PRURITUS (itching) and FEELING HOT (hot to touch) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.; Reporter's Comments: The event little more red. itching again, as reoccurred its not coded, its mentioned in the narrative
29 y/o male with swelling and pain of (L) arm from injection site to the elbow due to Anthrax innoculations. Pt educate to monitor site to F/U for further rxn.
The vaccine was painful as administered and my arm was sore but it was tolerable until about 5 hrs later when I was almost unable to move my arm because the pain was excruciating and I realized I had fever. I told Tylenol and was able to sleep a couple hrs but then shivered and had to lie flat on my back because of my arm and other pain throughout my body. My temp was just under 102 in the morning and after taking more Tylenol it reduced to 100 for most of the day. I spent the day in bed in considerable pain. Later in the evening I was able to get up and warm some food for my husband and me and I drank water. I gradually improved and slept better but was still achy and shaky the following day. I wish I had been warned that this was a possibility because i would not have scheduled the shot on Monday. I missed work on Tuesday and only managed to go in on Wed afternoon for a meeting.   I'm fine now but it really took me down for 2 days.
Patient received monovalent pfizer vaccine instead of bivalent pfizer vaccine as a booster dose. No adverse events
ENLARGED HEART; This spontaneous report received from a consumer concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced enlarged heart. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of enlarged heart was not reported. This report was non-serious.
Rash on hands and then spread all over the body which he is currently seeking treatment through the dermatologist.  Lesions have been biopsied and currently awaiting results.  Treatment is ointment with steroid and now on antibotics.  He also has some other issues down the road such renal/kidney failure and was hospitalized.
was found to be COVID-19 positive here, presenting with concern for three days of dysuria, urinary urgency, and frequency. EMS placed the patient on a nonrebreather and here she is saturating at 90%. She is tachycardic and tachypneic. Temperature here is 38.8° F.
Received inhaled vaccine in am seen at 4pm with swollen glands and purpurish lesions on tonsils and uvula.
Received 2nd Covid shot @ 9:45 a.m. at 10:45 pm. was dizzy, body aches, fever had low blood pressure, low pulse, low oxygen, cold sweats
After the vaccination, I was directed to take a seat at the medical facility in case of an adverse reaction. Afterwards, I left the medical facility and drove to work. As soon as I arrived at work (10 min drive), I began to feel dizzy, had slurred speech, I observed cognitive impairment, such as difficulty to coordinate my hand and feet movements. I informed my supervisor I had a reaction to the vaccine, drove to the hotel and noticed difficulty driving. When I arrived at the hotel I experienced an intense brain fog, and was unable to react to a coworker who knocked at my door to check on me, texts messages and phone calls. The symptoms I experienced kept me from calling my family, something I normally do every day. Those symptoms lasted approximately 20 hours.  I saw a doctor who told me I had an UTI and prescribed me an antibiotic. The same doctor told me that if I were older I would have died, because of the vaccine being administered while having an infection.  After that adverse reaction, I began experiencing headaches, heavy breathing during light physical activity, and memory loss. I also noticed I have difficulty learning and memorizing.
This spontaneous report as received from a healthcare worker refers to unspecified patients of unknown age and gender. There were no concomitant medications, concurrent conditions and medical history reported. On an unknown dates since 06-NOV-2015, the patients were vaccinated with PEDVAXHIB lot # L014429, expiration date 15-MAR-2018 (dose, site and route of administration were not reported), which were exposed to temperatures outside of the recommended range. There was no adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
The patient was treated for shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unspecified age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. In 2017, the patient was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date not reported) for the long-term prevention of shingles and/or zoster-related conditions. On an unknown date (reported as subsequent to patient's zoster vaccine live (ZOSTAVAX) inoculation), the patient was treated by a physician for shingles. As a direct and proximate result of patient's use of the zoster vaccine live (ZOSTAVAX), the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs included care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of the event was considered not recovered. The event was considered related to zoster vaccine live (ZOSTAVAX).
(R) thigh firm area under injection site. Size of lime per mom redness advised cool compress, ibuprofen for pain and inflammation.
Patient developed symptoms of MISC on 12/16/21; fevers began on 12/17/21 with a Tmax of 40 degrees Celsius.  Over the course of illness, symptoms and complications included fevers, shock, sinus tachycardia, hypotension, AKI, chest pain, shortness of breath, abdominal pain, rash, mucocutaneous lesions/conjunctivitis, headache, neck pain, and myalgias. Abnormal labs included elevated creatinine, elevated transaminases, thrombocytopenia, elevated NT-ProBNP, elevated CRP, elevated fibrinogen, elevated ferritin, and elevated D-dimer. ECHO studies showed pericardial effusion, pleural effusion, and trivial mitral regurgitation. Patient was admitted to the hospital on 12/20/21 and treated with IVIG, infliximab x 2, epinephrine, low flow nasal cannula, and aspirin. She was admitted to the ICU from 12/20/21 to 12/22/21. She was discharged on 12/24/2021.
While staffing observation, I (EMT) observed the patient to appear to be short of breath. The patient had removed her mask and was breathing rapidly with accessory muscle usage. I escorted the patient to the EMS Exam Room and called for my partner ( Paramedic) to assist me. While in the exam room we obtained a set of vitals. The patients vitals at 1545 were P:132, BP:160/90, Resp: 20, SpO2 91% on RA. After examining the patient, she stated that she had a history of MACs and was being treated for that at Clinic. The patent also stated that she had a history of cardiac problems but was unable to elaborate on what they were. After 15 minutes the patient was evaluated---
9 days after injection, developed  lump with itching and redness. Was warm to touch.   Narly a week later symptoms are subsiding.